Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05075967
Other study ID # HPTN 096
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date May 14, 2022
Est. completion date June 30, 2027

Study information

Verified date May 2023
Source HIV Prevention Trials Network
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

HPTN 096 is a community-randomized, controlled, hybrid-type III implementation effectiveness study. It is designed to evaluate an integrated strategy approach to increase the uptake and use of pre-exposure prophylaxis (PrEP) and viral suppression rates among Black MSM in the southern United States. A status-neutral approach will be taken such that Black MSM, regardless of HIV status (both those living with and without HIV), will be included in the study.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 4800
Est. completion date June 30, 2027
Est. primary completion date June 30, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 15 Years and older
Eligibility The baseline and post-implementation assessment participants will be persons who: - Self-identify as Black man (inclusive of cisgender and transgender men) - Self-report a lifetime history of sex with other men - Are at least 15 years of age - Self-report current residence in the community of interest - Are willing and able to provide informed consent - Agree to complete a short questionnaire - Agree to provide two blood samples (one by fingerstick and another by venipuncture). HIV status will not be ascertained prior to participation in these assessments and eligible Black MSM may participate regardless of HIV status.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Health Equity
This community-level structural component will use a standardized, nationally replicable community coalition model (Black Treatment Advocates Networks [BTAN]) to implement an enhanced program model geared to 1) facilitate the effects of the other HPTN 096 interventions by minimizing barriers to HIV testing, PrEP use and viral suppression through sensitizing a local network of service providers (e.g., social, legal, economic sectors) to the needs of Black MSM and maintaining an online platform for exchanging information about the local network that can be used to link Black MSM to resources and services, and 2) amplify the effects of other HPTN 096 components by increasing Black MSM's receptivity to those activities through the integration and promotion of HPTN 096 into the activities of the community coalition model.
Behavioral:
Social Media Influencers
In this community-level component, social media influencers (SMI) will be defined for the purposes of this study as users on social media who have established credibility, trust and access to a large audience of Black MSM, and who can persuade them by virtue of their authenticity and reach. SMI will provide tailored messaging for Black MSM in intervention communities on the topics of: HIV/sexually transmitted infections (STI) testing promotion PrEP (and general HIV prevention) awareness and promotion Definition and benefits of viral suppression. Messages may include direction towards health care facilities (HCFs) involved in the intersectional stigma reduction component and information about the virtual peer support platform or BTAN+ events.
Intersectional Stigma Reduction
This organizational-level component will take place in HCFs and is designed to improve cultural responsiveness in the provision of HIV prevention and health care services to Black MSM. It is expected to contribute to a reduction in HIV incidence by creating an affirming and autonomy-supportive healthcare environment that supports Black MSM engagement in HIV-related care and services and that promotes increased HIV/STI testing, PrEP uptake and viral suppression rates.
Peer Support
Peer support workers will be trained and compensated to provide emotional and practical support services. These peer support workers will have shared lived experiences with those whom they are supporting, be self-reflective of those experiences, and know when to share those experiences with others in an appropriate and supportive manner. Once trained, the peer-support workers will have demonstrated competencies in the following domains: HIV, PrEP, nPEP, other HIV prevention options and ART education Adherence to PrEP, ART and medical care HIV/STI testing New HIV diagnosis Addressing intersectional stigma (anti-Black racism, sexual stigmas, HIV-related stigma) Self-care Information about national and local resources and assistance programs, Black MSM-centered health services, and the cost and insurance coverage of medications and medical care Multicultural competency (as it relates to the HIV epidemic for Black MSM in the southern US)
Other:
Standard-of-care
Black MSM living in standard-of-care communities will have access to standard HIV prevention and care services available in their communities.

Locations

Country Name City State
United States FHI 360 Durham North Carolina

Sponsors (2)

Lead Sponsor Collaborator
HIV Prevention Trials Network Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Viral suppression in Black MSM living with diagnosed HIV (primary) The ratio of the number of Black MSM living with diagnosed HIV who are virally suppressed (<200 copies/mL) as measured by HIV surveillance data divided by the number of Black MSM living with diagnosed HIV as measured by HIV surveillance data Measured with data available at the end of the three year intervention
Primary Viral suppression in Black MSM living with diagnosed HIV (supportive) HIV viral load measured in the cross-sectional assessments Measured within six months after the end of the three year intervention
Primary PrEP use by Black MSM not living with HIV (primary) The presence of PrEP agents measured in a dried blood spot (DBS) collected during the cross-sectional assessments Measured within six months after the end of the three year intervention
Primary PrEP use by Black MSM not living with HIV (supportive) The ratio of the number of Black men with PrEP prescriptions (from AIDSVu) divided by the number of Black men with PrEP indications (from CDC) Measured with data available at the end of the three year intervention
Secondary Self-reported HIV Testing behavior in Black MSM Responses to survey questions collected during the post implementation cross-sectional assessment Measured within six months after the end of the three year intervention
Secondary Compare social support in Black MSM in the intervention to the SOC communities Responses to survey questions collected during the post-implementation cross-sectional assessment Measured within six months after the end of the three year intervention
Secondary Compare intersectional stigma in Black MSM in the intervention to the SOC communities Responses to survey questions collected during the post-implementation cross-sectional assessment Measured within six months after the end of the three year intervention
Secondary Compare barriers to healthcare in Black MSM in the intervention to the SOC communities Responses to survey questions collected during the post-implementation cross-sectional assessment Measured within six months after the end of the three year intervention
Secondary Compare individual agency in Black MSM in the intervention to the SOC communities Responses to survey questions collected during the post-implementation cross-sectional assessment Measured within six months after the end of the three year intervention
Secondary Viral suppression within 6 months of new diagnosis in Black MSM living with HIV The ratio of the number of Black MSM with HIV newly diagnosed in Year 3 who have a suppressed viral load (VL) within six months of diagnosis as measured by HIV surveillance data divided by the number of Black MSM with HIV newly diagnosed in Year 3 based on HIV surveillance data Measured with data available at the end of the three year intervention
Secondary Tracking EHE implementation activities for Black MSM Information about EHE implementation activities affecting Black MSM in the EHE plans of all intervention and control communities Measured with data available at the end of the three year intervention
Secondary Tracking EHE implementation activities for Black MSM Information about EHE implementation activities affecting Black MSM in additional information from local health departments and EHE committees Measured with data available at the end of the three year intervention
Secondary Care quality of Black MSM needs at HCFs participating in CRISP Self-reported survey data from health care workers who participate in the CRISP component Measured with data available at the end of the three year intervention
Secondary Care quality of Black MSM needs at HCFs participating in CRISP Aggregated, facility-level independent ratings of HCF workers Measured with data available at the end of the three year intervention
Secondary Care quality of Black MSM needs at HCFs participating in CRISP Self-reported survey data from Black MSM receiving services at HCFs participating in CRISP activities Measured with data available at the end of the three year intervention
Secondary Responsiveness to Black MSM needs at HCFs participating in CRISP Self-reported survey data from health care workers who participate in the CRISP component Measured with data available at the end of the three year intervention
Secondary Responsiveness to Black MSM needs at HCFs participating in CRISP Aggregated, facility-level independent ratings of HCF workers Measured with data available at the end of the three year intervention
Secondary Responsiveness to Black MSM needs at HCFs participating in CRISP Self-reported survey data from Black MSM receiving services at HCFs participating in CRISP activities Measured with data available at the end of the three year intervention
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2